AveXis Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Chicago, IL USA
Total Funding:$170.5M
Industry:Biotech
Founded:2010
Lead Investor(s):Goldman Sachs & Co. LLC, Jefferies LLC
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • AveXis's estimated annual revenue is currently $203.2M per year.
  • AveXis received $460.0M in venture funding in January 2018.
  • AveXis's estimated revenue per employee is $155,000
  • AveXis's total funding is $170.5M.

Employee Data

  • AveXis has 1311 Employees.
  • AveXis grew their employee count by 147% last year.
  • AveXis currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Chromatin
$6.5M42N/AN/A
Daigger
$3.4M22N/AN/A
Project Farma
$13.6M8847%N/A
Aptinyx
$6.7M60-14%N/A
Heidolph North ...
$8.5M5517%N/A
Orochem Technol...
$3.6M23N/AN/A
Horizon Therape...
$191.6M1236N/AN/A
Project Farma
$11.3M7324%N/A
AveXis
$203.2M1311147%N/A
zuChem
$2.2M14N/AN/A
Missing a competitor? Contribute!?
Submit

AveXis, Inc., a Novartis Company, is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and for the treatment of SMA Type 2. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1 and Type 2, we also plan to develop other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene. How to reach us: AveXis, Inc. 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: info@avexis.com Office Phone: 847.572.8280 Toll-free Phone: 844.4.AVEXIS (844.428.3947)

keywords:Biotechnology,Healthcare,Pharmaceuticals

1311

Number of Employees

$203.2M

Revenue (est)

1

Current Jobs

147%

Employee Growth %

$170.5M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Rod PulliamManager, Quality Assurance Document Control
Troy ShortVp - Supply ChainEmail Available
Angela NunnQc Manager - Sample Management, Stability, And Systems
Chad AllsburyDirector, Supply Chain
Cori SandyAssociate Director, Quality Systems
Eric MeinkeDirector, Analytical Sciences And Technology
Erich ErkerPlant Controller, Director Of Finance
Grant OndoAssociate Director Supplier Quality Management
John AdamsSenior Manager Of Engineering
Kris KellyDirector, Manufacturing Science And Technology

AveXis News

09/03/2019 - Warning signs were always there for Novartis's Avexis deal

High-profile departures at Avexis raise more questions about Novartis's acquisition, but there were plenty of red flags before the deal was ...

08/20/2019 - Ousted AveXis CSO denies wrongdoing in Novartis data ...

In a statement, former AveXis chief scientific officer Brian Kaspar said he "categorically denies any wrongdoing" in the Zolgensma data scandal.

09/03/2019 - Global Spinal Muscular Atrophy Medicine Market 2019 ...

The global market for Spinal Muscular Atrophy Medicine has been analyzed in an in-depth market research report recently added to the rapidly ...

AveXis Funding

DateAmountRoundLead InvestorsReference
2014-04-24$UndisclosedUndisclosedPBM Capital GroupArticle
2015-01-08$10.0MUndisclosedDeerfield ManagementArticle
2015-09-10$65.0MDT. Rowe Price AssociatesArticle
2017-06-21$230.0MUndisclosedGoldman Sachs & Co. LLCArticle
2018-01-17$460.0MUndisclosedGoldman Sachs & Co. LLCArticle

AveXis Executive Hires

DateNameTitleReference
2015-06-19Sean P. NolanChief Executive OfficerArticle
2016-07-12Michael B. JohannesenSVP General Counsel & Chief Compliance OfficerArticle
2017-02-16Rick ModiSVP/Chief Business OfficerArticle

AveXis New Location/Offices

DateLocationReference
2019-02-20Durham, NCArticle

AveXis Hiring Plans

DateNumber of EmployeesLocationReference
2019-02-20200North CarolinaArticle